Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have an available 8/8 human leukocyte antigen (HLA)-A, -B, -C, and -DRB1 matched-related or unrelated donor allogeneic hematopoietic peripheral blood stem cell graft.~* Acute myeloid leukemia, myelodysplasia, acute lymphoblastic leukemia, chronic myeloid leukemia, or myeloproliferative neoplasms requiring a matched allogeneic HSCT.~  * Acute Leukemia (AML or ALL) must be in complete remission defined as: \<5% marrow blasts with no morphologic evidence of leukemia, no peripheral blasts, marrow \>20% cellular, and peripheral absolute neutrophil count \>1000/µL (platelet recovery is not required).~ * Myelodysplasia (MDS) and chronic myeloid leukemia (CML): Must have \<5% marrow blasts.~ * Myeloproliferative neoplasms (MPN): Must have \<5% peripheral / marrow blasts.~* Adequate vital organ function:~  1. Left ventricular ejection fraction (LVEF) ≥ 45% by multi gated acquisition (MUGA) scan or ECHO~ 2. Forced expiratory volume at one second (FEV1), forced vital capacity (FVC), and adjusted diffusing lung capacity oxygenation (DLCO) ≥ 50% of predicted values on pulmonary function tests~ 3. Transaminases (AST, ALT) \< 2 times upper limit of normal values~ 4. Creatinine clearance ≥ 50 cc/min.~* Performance status: Karnofsky Performance Status Score ≥ 80%~* Donor eligibility: Eligible donors will include healthy sibling, relative or unrelated donors that are matched with the patient at HLA-A, B, C, and DRB1 by high resolution typing.~Exclusion Criteria:~* Active infection not controlled with appropriate antimicrobial therapy~* History of HIV, hepatitis B, or hepatitis C infection~* Anti-thymocyte globulin, alemtuzumab, bortezomib, or cyclophosphamide administered within 14 days before or planned to receive with HCT conditioning or as part of GVHD prophylaxis in the 14 days after HCT.~* Hypersensitivity to recombinant human IL-2~* Chronic lymphocytic leukemia, Hodgkin lymphoma, and non-hodgkin lymphoma are excluded as these malignancies may express the IL-2 receptor and pose a potential growth signal to any present disease.~* Sorror's co-morbidity factors with total score \>4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GVHD Regimen (Type: EXPERIMENTAL): Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).

Based on this trial design, predict the completion outcome and termination type (if applicable).